Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group

被引:163
作者
Conaghan, P. G. [1 ,2 ]
Hunter, D. J. [3 ,4 ,5 ]
Maillefert, J. F. [6 ,7 ,8 ]
Reichmann, W. M. [9 ,10 ]
Losina, E. [9 ,10 ]
机构
[1] Univ Leeds, Sect Musculoskeletal Dis, Leeds, W Yorkshire, England
[2] NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England
[3] Royal N Shore Hosp, Dept Rheumatol, Sydney, NSW, Australia
[4] Univ Sydney, No Clin Sch, Sydney, NSW 2006, Australia
[5] New England Baptist Hosp, Div Res, Boston, MA USA
[6] Dijon Univ Hosp, Dept Rheumatol, F-21078 Dijon, France
[7] Univ Burgondy, F-21079 Dijon, France
[8] INSERM, U887, F-21079 Dijon, France
[9] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA
[10] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA
关键词
Osteoarthritis; Conventional radiography; Magnetic resonance imaging; Validity; Responsiveness; Reliability; JOINT SPACE WIDTH; KNEE OSTEOARTHRITIS; RADIOGRAPHIC PROGRESSION; REPLACEMENT SURGERY; CARTILAGE LOSS; RESPONSIVENESS; RELIABILITY; VALIDITY; MARKERS; TRIALS;
D O I
10.1016/j.joca.2011.02.018
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
100224 [整形外科学];
摘要
Objective: The Osteoarthritis Research Society International initiated a number of working groups to address a call from the US Food and Drug Administration (FDA) on updating draft guidance on conduct of osteoarthritis (OA) clinical trials. The development of disease-modifying osteoarthritis drugs (DMOADs) remains challenging. The Assessment of Structural Change (ASC) Working Group aimed to provide a state-of-the-art critical update on imaging tools for OA clinical trials. Methods: The Group focussed on the performance metrics of conventional radiographs (CR) and magnetic resonance imaging (MRI), performing systematic literature reviews for these modalities. After acquiring these reviews, summary and research recommendations were developed through a consensus process. Results: For CR, there is some evidence for construct and predictive validity, with good evidence for reliability and responsiveness of metric measurement of joint space width (JSW). Trials off at least 1 and probably 2 years duration will be required. Although there is much less evidence for hip JSW, it may provide greater responsiveness than knee JSW. For MRI cartilage morphometry in knee OA, there is some evidence for construct and predictive validity, with good evidence for reliability and responsiveness. The responsiveness of semi-quantitative MRI assessment of cartilage morphology, bone marrow lesions and synovitis was also good in knee OA. Conclusions: Radiographic JSW is still a recommended option for trials of structure modification, with the understanding that the construct represents a number of pathologies and trial duration may be long. MRI is now recommended for clinical trials in terms of cartilage morphology assessment. It is important to study all the joint tissues of the OA joint and the literature is growing on MRI quantification (and its responsiveness) of non-cartilage features. The research recommendations provided will focus researchers on important issues such as determining how structural change within the relatively short duration of a trial reflects long-term change in patient-centred outcomes. (C) 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:606 / 610
页数:5
相关论文
共 22 条
[1]
Variation in Age and Physical Status Prior to Total Knee and Hip Replacement Surgery: A Comparison of Centers in Australia and Europe [J].
Ackerman, Ilana N. ;
Dieppe, Paul A. ;
March, Lyn M. ;
Roos, Ewa M. ;
Nilsdotter, Anna K. ;
Brown, Graeme C. ;
Sloan, Karen E. ;
Osborne, Richard H. .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (02) :166-173
[2]
The relationship between cartilage loss on magnetic resonance imaging and radiographic progression in men and women with knee osteoarthritis [J].
Amin, S ;
LaValley, MP ;
Guermazi, A ;
Grigoryan, M ;
Hunter, DJ ;
Clancy, M ;
Niu, JB ;
Gale, DR ;
Felson, DT .
ARTHRITIS AND RHEUMATISM, 2005, 52 (10) :3152-3159
[3]
[Anonymous], GUID CLIN INV MED PR
[4]
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee - Results of the two-year multinational knee osteoarthritis structural arthritis study [J].
Bingham, Clifton O., III ;
Buckland-Wright, J. Chris ;
Garnero, Patrick ;
Cohen, Stanley B. ;
DougadoS, Maxime ;
Adarni, Silvano ;
Clauw, Daniel J. ;
Spector, Timothy D. ;
Pelletier, Jean-Pierre ;
Raynauld, Jean-Pierre ;
Strand, Vibeke ;
Simon, Lee S. ;
Meyer, Joan M. ;
Cline, Gary A. ;
Beary, John F. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (11) :3494-3507
[5]
Yet more evidence that osteoarthritis is not a cartilage disease [J].
Brandt, K. D. ;
Radin, E. L. ;
Dieppe, P. A. ;
van de Putte, L. .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (10) :1261-1264
[6]
Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs [J].
Brandt, KD ;
Mazzuca, SA .
ARTHRITIS AND RHEUMATISM, 2005, 52 (11) :3349-3359
[7]
Effects of doxycycline on progression of osteoarthritis - Results of a randomized, placebo-controlled, double-blind trial [J].
Brandt, KD ;
Mazzuca, SA ;
Katz, BP ;
Lane, KA ;
Buckwalter, KA ;
Yocum, DE ;
Wolfe, F ;
Schnitzer, TJ ;
Moreland, LW ;
Manzi, S ;
Bradley, JD ;
Sharma, L ;
Oddis, CV ;
Hugenberg, ST ;
Heck, LW .
ARTHRITIS AND RHEUMATISM, 2005, 52 (07) :2015-2025
[8]
*CHMP, 1998, POINTS CONS CLIN INV
[9]
FDA, 1999, CLIN DEV PROGR DRUGS
[10]
Imaging in osteoarthritis [J].
Guermazi, Ali ;
Burstein, Deborah ;
Conaghan, Philip ;
Eckstein, Felix ;
Le Graverand-Gastineau, Marie-Pierre Hellio ;
Keen, Helen ;
Roemer, Frank W. .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2008, 34 (03) :645-+